{"groups":[{"description":"Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients \\<55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2\n\nHaplo HCT \\<55 years old: - Fludarabine (Flu)\n\n* Cyclophosphamide (Cy)\n* Melphalan (Mel)\n* Total body irradiation (TBI)\n* Non-T-cell depleted donor bone marrow stem cell infusion Day 0\n\nGVHD Prophylaxis: - Cyclophosphamide (Cy)\n\n* Tacrolimus (Tac)\n* Mycophenolate mofetil (MMF)","id":"FG000","title":"Arm A: Haplo-HCT <55 Years Old"},{"description":"Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.\n\nHaplo HCT ≥55 years old: - Fludarabine (Flu)\n\n* Cyclophosphamide (Cy)\n* Melphalan (Mel): Dose reduction by 30%\n* Total body irradiation (TBI)\n* Non-T-cell depleted donor bone marrow stem cell infusion\n\nGVHD Prophylaxis: - Cyclophosphamide (Cy)\n\n* Tacrolimus (Tac)\n* Mycophenolate mofetil (MMF)","id":"FG001","title":"CLOSED Arm B: Haplo-HCT ≥55 Years Old"},{"description":"Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2 aged ≥55 and \\< 65 years old.\n\nGVHD Prophylaxis: - Cyclophosphamide (Cy)\n\n* Tacrolimus (Tac)\n* Mycophenolate mofetil (MMF)\n\nHaplo HCT ≥55 and \\< 65 years old: - Fludarabine (Flu)\n\n* Cyclophosphamide (Cy)\n* Melphalan (Mel)\n* Total body irradiation (TBI)\n* non-T-cell depleted donor bone marrow stem cells","id":"FG002","title":"Arm C: Haplo-HCT HCT-CI ≤2 Aged ≥55 and < 65yo"},{"description":"Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients patients ≥65 and ≤75 years old OR any age group with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.\n\nGVHD Prophylaxis: - Cyclophosphamide (Cy)\n\n* Tacrolimus (Tac)\n* Mycophenolate mofetil (MMF)\n\nHaplo HCT ≥65 and ≤75 years old: - Fludarabine (Flu)\n\n* Cyclophosphamide (Cy)\n* Total body irradiation (TBI)","id":"FG003","title":"Arm D: Haplo-HCT Aged ≥65 and ≤75yo OR Any Age HCT-CI ≥3"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"14"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}